Research programme: anti-IL-13 monoclonal antibodies - Amgen

Drug Profile

Research programme: anti-IL-13 monoclonal antibodies - Amgen

Alternative Names: ABX 100122

Latest Information Update: 30 Mar 2010

Price : $50

At a glance

  • Originator Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 11 Sep 2008 Preclinical development is ongoing in the US
  • 03 Apr 2006 Preclinical trials in Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top